BOSTON, April 21, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the "Special Meeting") has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on April 11, 2025 (the "Special Meeting Proxy Stat

First patient in Cohort four has been treated with TTX-MC138Ten patients have been treated with TTX-MC138 at escalating dose levelsAdditional patients being evaluated for eligibility for expanded enrollmentNo significant safety or dose limiting toxicities have been reportedBOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being e

BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before deducting placement agent fees and offering expenses payable by the Company.

BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the shares of common stock and associated warrants are being offered by the Comp

Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3Patients currently being evaluated for Cohort 4 eligibilityPK and PD data from patients in Cohort 1 and Cohort 2 consistent with preclinical results and results from Phase 0 clinical trialBOSTON, March 13, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimous

BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today held the adjourned session of its Special Meeting from February 4, 2025, (the "Special Meeting").  Shareholders voted upon the two proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on December 30, 2024 (the "Special Meeting Proxy Statement"). The presence, by remote communication or by proxy, of the holders of at least one-third of the outstanding shares of capit

No significant safety or dose limiting toxicities reportedPK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial resultsBOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.  The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes av

BOSTON, Feb. 4, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on February 4, 2025 (the "Special Meeting") has been adjourned until February 25, 2025 at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on December 30, 2024 (the "Special Meeting Pro

Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial resultsBOSTON, Jan. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead candidate.  The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable

TransCode shares to remain listed on Nasdaq BOSTON, Jan. 7, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with Listing Rules 5550(a)(2) and 5550(b)(1), the Exchange's minimum bid price and shareholders' equity rules, respectively. The Company has also resolved the violation regarding Listing Rule 5635 (the "Shareholder Approval Rule") by obtaining shareholder ratification of a July 2024 equity transaction. As a result, the Company's shares will remain lis

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4/A - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios.  He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. "Dr. Slack is one of the most preeminent scientists in the field of small noncoding RNA," commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. "Having pioneered pivotal studies proving that microRNAs drive oncogenesis and represent critical targets for the treatment of cancer, his guidance will prove indispensable as TransCode enters the clinical phase of development." Dr. Slack is the Shields Warren Mallinckrodt Profe